NICE changes its mind on Imbruvica for mantle cell lymphoma

14 December 2017
2019_biotech_test_vial_discovery_big

In a reversal of a previous guidance, the UK’s National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending ibrutinib (or routine National Health Service (NHS) use to treat mantle cell lymphoma (MCL) in people who have had only one prior line of therapy.

US healthcare giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Imbruvica (ibrutinib) is currently available to patients in the Cancer Drugs Fund (CDF). It is used to treat patients if their cancer has come back or not responded to first-line treatment. It is considered a life-extending treatment at the end-of-life.

Back in September the cost-effectiveness watchdog rejected the drug for the treatment of mantle cell lymphoma on the NHS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology